If You Invested $1,000 in Gilead Sciences' IPO, This Is How Much Money You'd Have Now
Gilead Sciences priced its shares at $15 before its IPO. Still, though, a $10,000 investment in Gilead's IPO would now be worth nearly $1.8 million. Vistide was the beginning of a long and successful road for Gilead in treating HIV-related conditions. Gilead is also evaluating drugs that could potentially cure HIV in early stage clinical studies.
ipo drug gileads
GoogleRelated Articles
Drug tested at UVA cleared as 1st COVID-19 treatment
“We are immensely grateful to the patients who participated in this important clinical trial and their families,” said Patrick Jackson, MD, the trial’s principal investigator at UVA. Tested at UVA Health and 67 other sites around the world, remdesivir helped patients with advanced cases of COVID-19 recover 31% faster than patients who received a placebo, according to preliminary trial results released by the National Institutes of Health.
drug
Whsv
Experiments going on for a coronavirus vaccine
An experimental coronavirus treatment that was halted a week ago due to "overwhelming" demand is once again available to doctors under an expanded access program. On Saturday, Gilead Sciences CEO Daniel O’Day announced in an open letter that his company was once again making remdesivir available outside of the six ongoing clinical trials investigating whether it is effective as a treatment for COVID-19
drug treatment week
Google
"In the next 12 months, many crypto companies will go public" - Brad Garlinghouse
Ripple CEO, Brad Garlinghouse hinted that the Ripple could file for an IPO as soon as by December 2020. Speaking at the World Economic Forum in Davos, Galinghouse mentioned that in the next 12 months you'll see a lot of crypto companies filing for IPOs, and I expect Ripple to be on the leading side as its a natural evolution for our company.
ceo blockchain ipo crypto ripple
Cointelegraph
Saudi-owned Aramco exercises greenshoe option, raises IPO to record $29.4b
Saudi Arabia's state-owned Aramco, currently by far the the most valuable company in the world at 1.87 trillion USD, has revealed that it exercised its 'greenshoe option' to raise its IPO to a record 29.4 billion USD. The greenshoe option, also called over-allotment, allows a company to issue more shares in its IPO when there is greater demand from initial investors.
saudi-arabia aramco ipo world record company investor trillion valuable greenshoe-option over-allotment
Reuters